Multiple Sclerosis Therapy: Are We Ready for a One-Size-Fits-All Approach?

J Neuroophthalmol. 2018 Jun;38(2):258-262. doi: 10.1097/WNO.0000000000000640.
No abstract available

Publication types

  • Review

MeSH terms

  • Age of Onset
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antirheumatic Agents / therapeutic use
  • Female
  • Humans
  • Immunologic Factors / therapeutic use
  • Male
  • Multiple Sclerosis / epidemiology
  • Multiple Sclerosis / therapy*
  • Sex Factors

Substances

  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Immunologic Factors
  • ocrelizumab